Requirements for anti-tuberculosis drug tender requests

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 11 SUPPL. 3, 1999, Pages

  Trébucq, Arnaud ^a   Caudron, J M ^b   Pinel, J ^c  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^b MÉDECINS SANS FRONTIÈRES   (Belgium)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

Bioavailability; Drug tenders; Fixed dose combinations; Tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

CONFERENCE PAPER; DRUG COST; DRUG FORMULATION; DRUG MARKETING; DRUG QUALITY; DRUG USE; PRIORITY JOURNAL;

ADULT; ANTITUBERCULAR AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHILD; COMPETITIVE BIDDING; DRUG AND NARCOTIC CONTROL; DRUG COMBINATIONS; DRUG INDUSTRY; HUMANS; NATIONAL HEALTH PROGRAMS; QUALITY CONTROL; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 0344374439     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Pillai G, Fourie P B, Padayatchi N, et al. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S309-S316.
2. O'Brien K L, Selanikio J D, Heckdivert C, et al. Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning. JAMA 1998; 279: 1175-1180.
3. Shakoor O, Taylor R B, Behrens R H. Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health 1997; 2: 839-845.
4. Pinel J, Varaine F, Fermon F, Marchant G, Maritoux J. Des faux vaccins anti-méningocoques lors d'une épidémie de méningita au Niger. Phénomène isolé ou généralisation des circuits criminels ? Méd Mal Infect 1997; 27(No spécial): 563.
5. Managing Drug Supply. MSH/WHO, Geneva, Switzerland: WHO, 1996.
6. Guidelines for implementation of the WHO certification scheme on the quality of pharmaceutical products moving in international commerce. WHO Technical Report Series, No863, 1996. Updated list of Participating Countries in 1997, WHO/ PHARM/82.4 Rev 5. Geneva, Switzerland: WHO, 1996.
7. Enarson D A, Rieder H L, Arnadottir T, Trébucq A. Tuberculosis guide for low income countries. 4th ed. International Union Against Tuberculosis and Lung Disease. Frankfurt, Germany: pmi Verlagsgruppe GmbH, 1996.
8. Maher D, Chaulet P, Spinaci S, Harries H. Treatment of tuberculosis: guidelines for national programmes. WHO/TB/97.220. Geneva, Switzerland: WHO, 1997.
9. Sbarbaro J A. Multidrug-resistant tuberculosis. Chest 1997; 111: 1149-1151.
10. Ellard G A, Fourie P B. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S301-S308.
11. Quality assurance: protocol for assessing the rifampicin bioavailability of combined formulations in healthy volunteers. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S284-S285.
12. International Union Against Tuberculosis and Lung Disease/ World Health Organization. Assuring bioavailability of fixed-dose combinations of anti-tuberculosis medications. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S282-S283.